- Home
- FREY vs KMDA Comparison
FREY vs KMDA Comparison
Compare FREY & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FREY
- KMDA
- Stock Information
- Founded
- FREY 2018
- KMDA 1990
- Country
- FREY Luxembourg
- KMDA Israel
- Employees
- FREY N/A
- KMDA N/A
- Industry
- FREY Industrial Machinery/Components
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- FREY Miscellaneous
- KMDA Health Care
- Exchange
- FREY Nasdaq
- KMDA Nasdaq
- Market Cap
- FREY 364.9M
- KMDA 349.6M
- IPO Year
- FREY N/A
- KMDA N/A
- Fundamental
- Price
- FREY $2.29
- KMDA $7.08
- Analyst Decision
- FREY
- KMDA Strong Buy
- Analyst Count
- FREY 0
- KMDA 2
- Target Price
- FREY N/A
- KMDA $14.50
- AVG Volume (30 Days)
- FREY 3.9M
- KMDA 143.6K
- Earning Date
- FREY 02-27-2025
- KMDA 03-05-2025
- Dividend Yield
- FREY N/A
- KMDA N/A
- EPS Growth
- FREY N/A
- KMDA 124.29
- EPS
- FREY N/A
- KMDA 0.27
- Revenue
- FREY N/A
- KMDA $158,380,000.00
- Revenue This Year
- FREY N/A
- KMDA $15.37
- Revenue Next Year
- FREY $414.23
- KMDA $8.58
- P/E Ratio
- FREY N/A
- KMDA $25.99
- Revenue Growth
- FREY N/A
- KMDA 4.52
- 52 Week Low
- FREY $0.91
- KMDA $4.74
- 52 Week High
- FREY $3.36
- KMDA $8.00
- Technical
- Relative Strength Index (RSI)
- FREY 48.23
- KMDA 66.54
- Support Level
- FREY $2.11
- KMDA $7.00
- Resistance Level
- FREY $2.71
- KMDA $7.23
- Average True Range (ATR)
- FREY 0.25
- KMDA 0.32
- MACD
- FREY -0.06
- KMDA 0.04
- Stochastic Oscillator
- FREY 18.95
- KMDA 56.81
About FREY FREYR Battery Inc.
FREYR Battery Inc is an emerging producer of clean battery solutions for the planet. It designs and manufactures high-density and cost-competitive lithium-ion batteries with a reduced carbon footprint for the markets for electric mobility, stationary energy storage, and marine and aviation applications.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.